Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Bafilomycin A1: Selective V-ATPase Inhibitor for Intracel...

    2026-01-13

    Bafilomycin A1: Selective V-ATPase Inhibitor for Intracellular pH and Lysosomal Function Research

    Executive Summary: Bafilomycin A1 is a crystalline, cell-permeable inhibitor of vacuolar H+-ATPases (V-ATPases), with potent activity in the nanomolar range (APExBIO). It reversibly blocks proton translocation, enabling precise control of lysosomal acidification and intracellular pH. Quantitative benchmarks confirm complete V-ATPase inhibition at 10 nM in vitro and functional effects in cell and animal models (Vicente et al., 2025). The inhibitor is foundational for studies in osteoclast biology, cancer, neurodegenerative disease, and autophagy. APExBIO's Bafilomycin A1 (SKU A8627) is validated for solubility, stability, and reproducibility in advanced research workflows.

    Biological Rationale

    Vacuolar-type H+-ATPases (V-ATPases) are ATP-dependent proton pumps that acidify intracellular organelles, including lysosomes, endosomes, and secretory vesicles. Acidification is essential for proteolytic degradation, receptor recycling, and signaling (Vicente et al., 2025). Disruption of V-ATPase function impairs lysosomal activity, autophagy, and pH homeostasis. In osteoclasts, V-ATPases facilitate bone resorption by secreting protons into the resorption lacuna. Aberrant V-ATPase activity is implicated in cancer progression, neurodegenerative diseases, and infectious disease susceptibility. Selective pharmacological tools such as Bafilomycin A1 are required to dissect these pathways with high specificity (Protein G Beads, 2024).

    Mechanism of Action of Bafilomycin A1

    Bafilomycin A1 is a macrolide antibiotic produced by Streptomyces griseus. It binds the c subunit of V-ATPase, blocking ATP-driven proton translocation across organellar membranes. This inhibition is selective and reversible, with reported IC50 values ranging from 4 to 400 nM, depending on enzyme source and assay conditions (APExBIO). Complete inhibition of V-ATPase proton transport is observed at concentrations as low as 10 nM in vitro. Bafilomycin A1 does not significantly affect other ATPases at these concentrations, supporting its selectivity (Vatalis, 2024). The compound is soluble in DMSO at concentrations greater than 10 mM and is supplied as a crystalline solid for research use.

    Evidence & Benchmarks

    • Bafilomycin A1 inhibits V-ATPase-dependent proton transport in vitro with an IC50 as low as 4 nM, achieving full blockade at 10 nM (APExBIO product documentation: link).
    • In HeLa cells, Bafilomycin A1 dose-dependently reverses vacuolization induced by Helicobacter pylori; 50% effect at 4 nM, complete normalization at 12.5 nM (APExBIO).
    • In young freshwater tilapia (Oreochromis mossambicus), Bafilomycin A1 inhibits branchial Na+ uptake with a Ki of 1.6 × 10⁻⁷ mol/L, confirming cross-species efficacy (Vicente et al., 2025).
    • Bafilomycin A1 is widely adopted in studies of autophagy, lysosomal function, osteoclast-mediated bone resorption, and intracellular pH regulation (Protein G Beads, 2024).
    • Stock solutions in DMSO are stable for several months below -20°C; solutions are not recommended for long-term storage (APExBIO).
    • Bafilomycin A1 does not inhibit non-V-ATPases at recommended concentrations, minimizing off-target effects (Vatalis, 2024).

    Applications, Limits & Misconceptions

    Bafilomycin A1 is a gold-standard reagent for dissecting the role of V-ATPases in cell biology, with applications in:

    Common Pitfalls or Misconceptions

    • Bafilomycin A1 is not a pan-ATPase inhibitor; it is selective for V-ATPases at recommended concentrations.
    • It does not reliably induce apoptosis; its primary effect is on autophagic and lysosomal pathways.
    • Stock solutions are stable in DMSO at -20°C, but aqueous solutions degrade rapidly and should not be stored long-term.
    • Bafilomycin A1 does not block all forms of proton transport; mitochondrial ATPases and plasma membrane H+-ATPases are unaffected at standard doses.
    • In some cell types, compensatory pH-regulating mechanisms may attenuate observed effects.

    Workflow Integration & Parameters

    Bafilomycin A1 (SKU A8627) from APExBIO is supplied as a crystalline solid, soluble in DMSO above 10 mM. For cell culture, working concentrations of 4–100 nM are typical, depending on cell type and endpoint. Solutions should be prepared fresh or stored below -20°C for up to several months. Avoid repeated freeze-thaw cycles. Use of validated controls and parallel vehicle treatments is recommended. Shipping is performed on Blue Ice for temperature stability. For detailed workflow guidance, see scenario-driven protocols in HOBt-Anhydrous; this article updates with current storage and solubility data.

    Conclusion & Outlook

    Bafilomycin A1 remains the benchmark tool for selective, reversible inhibition of V-ATPase activity in cell and animal models. Its nanomolar potency, stability profile, and robust documentation support reproducible results in pH regulation, lysosomal function, and related fields. APExBIO's validated product and technical resources further improve confidence in experimental design. Ongoing research continues to reveal new applications in cancer, neurodegeneration, and host-pathogen interactions. For more information or to order, visit the APExBIO Bafilomycin A1 product page.